PREFERRED FIRST-LINE REGIMEN OPTIONS FOR PATIENTS WITH METASTATIC PANCREATIC CANCER AND GOOD PS1,6 PREFERRED FIRST-LINE REGIMEN OPTIONS FOR PATIENTS WITH METASTATIC PANCREATIC CANCER AND GOOD PS1,6

Both albumin-bound paclitaxel (ABRAXANE) + gemcitabine and FOLFIRINOX are preferred first-line regimens for patients with good performance status (PS)a in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 for metastatic pancreatic cancer12
ABRAXANE + gemcitabine & FOLFIRINOX are NCCN Category 1 preferred first line regimens for patients with metastatic pancreatic cancer and good PS ABRAXANE + gemcitabine & FOLFIRINOX are NCCN Category 1 preferred first line regimens for patients with metastatic pancreatic cancer and good PS
There have been no head-to-head clinical trials comparing safety and efficacy of albumin-bound paclitaxel (ABRAXANE) + gemcitabine and FOLFIRINOX
Additional first-line Category 1 regimens for metastatic disease include gemcitabine monotherapy and gemcitabine + erlotinib.12

  • aGood performance status is defined as ECOG 0-1 with patent biliary stent and adequate nutritional intake.
  • bCategory 1: Based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate.

    Please refer to the NCCN Guidelines® for pancreatic cancer for a complete list of recommended treatment options, including Category 2A and 2B treatment options for metastatic patients with good performance status.

YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL